Proactive Mid + Small highlights - Marechale, Cellcast, Daniel Stewart, Gable Holdings, Connemara Mining, Velocys

Marechale investors had a day in the sun, while Babestation owner Cellcast was the week's second biggest riser

A solar project was recommended, but still there's a wait for a decision

Marechale Capital (LON:MAC) soared 500% as the company said a planning application for a solar project was recommended to a committee but no decision has yet been made.

Babestation owner Cellcast Group (LON:CLTV) advance 52% and was the week’s second-biggest riser amid talk of interest from Google.

The search giant, soon to be re-christened Alphabet, is said to be interested in Cellcast’s internet technology - which allows viewers to interact with TV programmes through their mobiles.

While the rumours have been categorically denied, investors obviously believe something is going on.

Speculators were similarly unwilling to take the hint when it came to quoted City broker Daniel Stewart (LON:DAN), whose shares have surged 30% this week.

The reasoning for the renaissance – belief that former Quindell boss Rob Terry’s investment vehicle, Quob Park Estate, might raise its stake in the business above the 9.99% it currently has.

Earlier this week the Financial Conduct Authority said it was dropping its probe into Quindell to allow Serious Fraud Office to carry out its criminal inquiry.

The FCA’s decision to exit, according to some misguided souls, would allow Terry to bid for DS.

Not so. Via Quob Park he said on August 5 that he wouldn’t buy any further shares until all the investigations into Quindell are concluded – there are currently two ongoing.

Elsewhere there was buying interest in insurer Gable Holdings (LON:GAH), up 49% after a short, but upbeat trading update, and Ireland focused zinc exploration firm Connemara Mining (LON:CON),up 40%, which is led by serial entrepreneur John Teeling.

Among the losers, Velocys (LON:VLS) was down 20% this weeks as investors continued to react to the shock departure of boss Roy Lipski, who had been with the business nine-and-a-half years. In the last three months the stock has lost more than half of its value.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

15 hours, 18 minutes ago

2 min read